|
Jul 1
|
Bristol Myers Squibb (BMY) Ascends While Market Falls: Some Facts to Note
|
|
Jul 1
|
Pfizer's Strong Late-Stage Pipeline Can Drive Long-Term Growth
|
|
Jun 30
|
Are Options Traders Betting on a Big Move in Bristol-Myers Squibb Stock?
|
|
Jun 30
|
BMY Loses 16.3% YTD: Should You Buy, Sell or Hold the Stock?
|
|
Jun 30
|
Jim Cramer Highlights That Incyte’s New CEO is an “Industry Veteran”
|
|
Jun 30
|
AbbVie to buy Capstan for up to $2.1 billion in immunology push
|
|
Jun 27
|
FDA approves label updates for BMS’ CAR T cell therapies
|
|
Jun 27
|
Sickle Cell Disease Treatment Market Analysis and Forecast, 2025-2035 | Intensifying Competition as Key Players Advance Gene and Novel Therapies
|
|
Jun 27
|
U.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb’s Cell Therapy Labels
|
|
Jun 26
|
Incyte's New CEO Is A Dealmaking Machine. Will He Bring That Fervor To His New Role?
|
|
Jun 26
|
Will MRK's Growing Pipeline Help Navigate the Looming Keytruda LOE?
|
|
Jun 26
|
Incyte replaces CEO Hoppenot with dealmaker Meury
|
|
Jun 25
|
Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst
|
|
Jun 25
|
Will New Drugs Enable BMY to Offset the Impact of Generic Competition?
|
|
Jun 25
|
3 Top Dividend Stocks to Maximize Your Retirement Income
|
|
Jun 24
|
BMY Declares $0.60 Dividend, Extends 95-Year Streak
|
|
Jun 24
|
Cigna Sues Bristol Myers Over Alleged Monopoly on Cancer Drug Pomalyst
|
|
Jun 24
|
EXEL Stock Rises on Positive Data From Colorectal Cancer Study
|
|
Jun 24
|
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
|
|
Jun 20
|
The Top 5 Analyst Questions From Bristol-Myers Squibb’s Q1 Earnings Call
|